Amol Akhade/LinkedIn
Apr 23, 2025, 19:57
Amol Akhade: Which ADC target in SCLC holds the most promise?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospital, shared on LinkedIn:
“ADCs in Small Cell Lung Cancer (SCLC): All active 2L/3L+ agents summarized in one slide.
The therapeutic landscape in SCLC is evolving beyond platinum-etoposide and immunotherapy. Multiple antibody–drug conjugates (ADCs) are now in clinical development—targeting DLL3, B7-H3, TROP2, and SEZ6, with diverse payloads and toxicity profiles.
This one-slide summary includes:
All active ADCs in phase 1–3 trials Targets and payloads (SN-38, deruxtecan, calicheamicin…) 🏢 Developing companies (Gilead, AstraZeneca, AbbVie…) ORR, PFS, OS where available. Toxicity highlights from early-phase data
From the lessons of Rova-T to the promise of B7-H3 (GSK5764227, MGC018) and SEZ6 (ABBV-011, ABBV-706), the ADC pipeline in SCLC is rich—and rapidly evolving.
This is useful for:
- Oncologists and thoracic investigators
- Biotech and trial strategy teams
- Medical Affairs and MSL teams
- Anyone tracking ADCs in solid tumors
Which ADC target in SCLC holds the most promise – DLL3, B7-H3, TROP2, or SEZ6?”
More posts related to ADCs on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 19:57
Apr 23, 2025, 17:10
Apr 23, 2025, 16:51